MedPath

Loteprednol

Generic Name
Loteprednol
Brand Names
Alrex, Lotemax, Zylet
Drug Type
Small Molecule
Chemical Formula
C21H27ClO5
CAS Number
129260-79-3
Unique Ingredient Identifier
Z8CBU6KR16
Indication

用于眼科局部炎症。0.2％浓度适用于暂时缓解季节性过敏性结膜炎；0.5％混悬液适用于治疗对类固醇有效的炎症，如结膜炎、角膜、前房炎、过敏性结膜炎、痤疮、酒糟鼻、表浅性点状角膜炎、疱疹、带状疱疹角膜炎、虹膜炎、睫状体炎等可适当减轻水肿和炎症。尚可用于眼科手术后炎症的治疗。

Associated Conditions
Chickenpox, Conjunctivitis infective, Cyclitis, Eye infection viral, Herpes Zoster Keratitis, Inflammation, Iritis, Ocular Inflammation, Rosacea, Seasonal Allergic Conjunctivitis, Superficial punctate keratitis
Clinical Trials
Related News

LE Gel for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery

Phase 3
Completed
Conditions
Ocular Inflammation
Cataract
Pain
Interventions
Drug: Vehicle Gel
First Posted Date
2016-06-01
Last Posted Date
2021-01-08
Lead Sponsor
Bausch & Lomb Incorporated
Target Recruit Count
600
Registration Number
NCT02786901
Locations
🇺🇸

Valeant Site 01, Phoenix, Arizona, United States

🇺🇸

Valeant Site 02, Saint Louis, Missouri, United States

🇺🇸

Valeant Site 05, Miami, Florida, United States

and more 3 locations

Safety and Efficacy of KPI-121 in Subjects With Inflammatory Meibomian Gland Disease

Phase 2
Completed
Conditions
Blepharitis
Interventions
Drug: Vehicle
First Posted Date
2014-08-18
Last Posted Date
2021-01-11
Lead Sponsor
Kala Pharmaceuticals, Inc.
Target Recruit Count
206
Registration Number
NCT02218489
Locations
🇺🇸

Abrams Eye Center, Cleveland, Ohio, United States

🇺🇸

Sall Research Medical Center, Artesia, California, United States

🇺🇸

Wolstan & Goldberg Eye Associates, Torrance, California, United States

and more 5 locations

Topical Steroid Treatment For Dry Eye

Not Applicable
Conditions
Dry Eye
Interventions
First Posted Date
2014-08-18
Last Posted Date
2014-08-18
Lead Sponsor
Meir Medical Center
Target Recruit Count
30
Registration Number
NCT02218827
Locations
🇮🇱

Sheba Medical Center, Ramat Gan, Israel

🇮🇱

Meir Medical center, Kfar Saba, Israel

Loteprednol Etabonate Ophthalmic Gel for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery

Phase 3
Completed
Conditions
Inflammation
Pain
Cataract
Interventions
Drug: Vehicle Gel (BID)
First Posted Date
2014-08-05
Last Posted Date
2020-09-25
Lead Sponsor
Bausch & Lomb Incorporated
Target Recruit Count
326
Registration Number
NCT02208297
Locations
🇺🇸

Bausch & Lomb Incorporated, Bridgewater, New Jersey, United States

Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease

Phase 2
Completed
Conditions
Dry Eye Syndromes
Keratoconjunctivitis Sicca
Interventions
Drug: Placebo
First Posted Date
2014-07-11
Last Posted Date
2021-01-06
Lead Sponsor
Kala Pharmaceuticals, Inc.
Target Recruit Count
150
Registration Number
NCT02188160
Locations
🇺🇸

Eye Center of Southern CT, P.C., Hamden, Connecticut, United States

🇺🇸

Total Eye Care, PA, Memphis, Tennessee, United States

🇺🇸

Martel Eye Medical Group, Rancho Cordova, California, United States

and more 8 locations

The Utility of IVCM to Assess Cellular Response and Efficacy of Long-term Topical Steroid Treatment in Patients With DED

Phase 4
Completed
Conditions
Dry Eye Disease
Interventions
Drug: Soothe Tired Eyes Lubricant Eye Drop (Artificial Tears)
Diagnostic Test: In Vivo Confocal Microscopy (IVCM)
First Posted Date
2014-04-22
Last Posted Date
2024-06-26
Lead Sponsor
Tufts Medical Center
Target Recruit Count
37
Registration Number
NCT02120079
Locations
🇺🇸

Tufts Medical Center, Boston, Massachusetts, United States

Loteprednol Ophthalmic Gel for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery

Phase 3
Completed
Conditions
Inflammation
Pain
Cataract
Interventions
Drug: Vehicle (BID)
Drug: Vehicle (TID)
First Posted Date
2013-11-27
Last Posted Date
2020-09-25
Lead Sponsor
Bausch & Lomb Incorporated
Target Recruit Count
514
Registration Number
NCT01996839
Locations
🇺🇸

Bausch & Lomb Incorporated, Bridgewater, New Jersey, United States

Lotemax® Gel 0.5% and Restasis 0.05% in Participants With Mild or Moderate Keratoconjunctivitis Sicca (Dry Eye Disease)

Phase 2
Completed
Conditions
Keratoconjunctivitis Sicca
Interventions
Drug: Soothe® Lubricant Eye Drops
First Posted Date
2013-03-25
Last Posted Date
2019-08-30
Lead Sponsor
Bausch & Lomb Incorporated
Target Recruit Count
102
Registration Number
NCT01817582
Locations
🇺🇸

Bausch & Lomb Incorporated, Irvine, California, United States

Efficacy of Loteprednol Ointment Following Eyelid Surgery

Not Applicable
Withdrawn
Conditions
Post-operative Healing Following Blepharoplasty and Ptosis Repair
Interventions
Drug: Vehicle Ophthalmic Ointment
First Posted Date
2012-12-13
Last Posted Date
2019-08-02
Lead Sponsor
University of California, San Diego
Registration Number
NCT01749241
Locations
🇺🇸

Shiley Eye Center, La Jolla, California, United States

Treatment of Ocular Graft-versus-Host Disease (GVHD) With Topical Loteprednol Etabonate 0.5%

Not Applicable
Completed
Conditions
Dry Eyes
Interventions
First Posted Date
2012-09-28
Last Posted Date
2015-09-24
Lead Sponsor
University of Michigan
Target Recruit Count
75
Registration Number
NCT01695668
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy